FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.
Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagozdzon A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M.
Pyrzynska B, et al. Among authors: gobessi s.
Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29721381
Free PMC article.